- Home
- ACRS vs MNSB Comparison
ACRS vs MNSB Comparison
Compare ACRS & MNSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- MNSB
- Stock Information
- Founded
- ACRS 2012
- MNSB 2003
- Country
- ACRS United States
- MNSB United States
- Employees
- ACRS N/A
- MNSB N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- MNSB Major Banks
- Sector
- ACRS Health Care
- MNSB Finance
- Exchange
- ACRS Nasdaq
- MNSB Nasdaq
- Market Cap
- ACRS 165.7M
- MNSB 149.7M
- IPO Year
- ACRS 2015
- MNSB N/A
- Fundamental
- Price
- ACRS $1.80
- MNSB $22.79
- Analyst Decision
- ACRS Strong Buy
- MNSB
- Analyst Count
- ACRS 9
- MNSB 0
- Target Price
- ACRS $9.25
- MNSB N/A
- AVG Volume (30 Days)
- ACRS 1.4M
- MNSB 17.8K
- Earning Date
- ACRS 08-07-2025
- MNSB 07-22-2025
- Dividend Yield
- ACRS N/A
- MNSB 1.84%
- EPS Growth
- ACRS N/A
- MNSB N/A
- EPS
- ACRS N/A
- MNSB N/A
- Revenue
- ACRS $16,789,000.00
- MNSB $64,604,000.00
- Revenue This Year
- ACRS N/A
- MNSB $17.95
- Revenue Next Year
- ACRS $8.11
- MNSB $2.52
- P/E Ratio
- ACRS N/A
- MNSB N/A
- Revenue Growth
- ACRS N/A
- MNSB N/A
- 52 Week Low
- ACRS $1.05
- MNSB $15.00
- 52 Week High
- ACRS $5.17
- MNSB $22.85
- Technical
- Relative Strength Index (RSI)
- ACRS 62.45
- MNSB 74.68
- Support Level
- ACRS $1.75
- MNSB $19.51
- Resistance Level
- ACRS $1.92
- MNSB $22.00
- Average True Range (ATR)
- ACRS 0.09
- MNSB 0.46
- MACD
- ACRS 0.01
- MNSB 0.15
- Stochastic Oscillator
- ACRS 70.00
- MNSB 98.20
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.